Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-08-29
2006-08-29
Schultz, J. D. (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S023100, C536S024300, C536S024500, C435S006120
Reexamination Certificate
active
07098192
ABSTRACT:
Compounds, compositions and methods are provided for inhibiting the expression of human STAT3. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding STAT3. Methods of using these oligonucleotides for inhibition of STAT3 expression and for promotion of apoptosis are provided. Methods for treatment of diseases, particularly inflammatory diseases and cancers, associated with overexpression or constitutive activation of STAT3 or insufficient apoptosis are also provided.
REFERENCES:
patent: 5719042 (1998-02-01), Kishimoto et al.
patent: 5801154 (1998-09-01), Baracchini et al.
patent: 5844082 (1998-12-01), Kishimoto et al.
patent: 6159694 (2000-12-01), Karras
patent: 6248586 (2001-06-01), Monia et al.
patent: 6727084 (2004-04-01), Hoyoux et al.
patent: WO 00/61602 (2000-10-01), None
Konnikova, et al. Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells, BMC Cancer, Sep. 2003, vol. 3, pp. 1-9.
Aberg, et al., Selective Introduction of Antisense Oligonucleotides into Single Adult CNS Progenitor Cells Using Electroporation Demonstrates the Requirement of STAT3 Activation for CNTF-Induced Glogenesis, Molecular and Cellular Neuroscience, 2001; vol. 17, pp. 426-443.
PCT International Search Report and Written Opinion for International application No. PCT/US04/32130, filed Sep. 30, 2004. Search report dated Apr. 25, 2005. 8 pages.
Agrawal, S., “Antisense oligonucleotides: towards clinical trials,”TIBTECH(1996) 14(10):376-387.
Barton, B. E. et al., “Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: Direct STAT3 inhibition induces apoptosis in prostate cancer lines,”Mol. Cancer Ther. (2004) 3(1): 11-20.
Braasch, D. A. et al., “Novel Antisense and Peptide Nucleic Acid Strategies for Controlling Gene Expression,”Biochem. (2002) 41(14): 4503-4510.
Branch, A. D., “A good antisense molecule is hard to find,”TIBS(1998) 23(2): 45-50.
Epling-Burnette, P. K. et al., “Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression,”J. Clin. Invest. (2001) 107(3): 351-361.
Gewirtz, A. M. et al., “Facilitating oligonucleotide delivery: Helping antisense deliver on its promist,”Proc. Natl. Acad. Sci. USA(1996) 93: 3161-3163.
Grandis, J. R. et al., “Requirement of Stat3 but not Stat1 Activation for Epidermal Growth Factor Receptor-mediated Cell Growth In Vitro,”J. Clin. Invest. (1998) 102(7): 1385-1392.
Karras, J. G. et al., “STAT3 Regulates the Growth and Immunoglobulin Production of BCL1B Cell Lymphoma through Control of Cell Cycle Progression,”Cell. Immunol. (2000) 202:124-135.
Lamy, T. et al., “Dysregulation of CD95/CD95 Ligand-Apoptotic Pathway in CD3+Large Granular Lymphocyte Leukemia,”Blood(1998) 92(12): 4771-4777.
Liu, H. et al., “Serine phosphorylation of STATE3 is essential for Mcl-1 expression and macrophage survival,”Blood(2003) 102(1): 344-352
Mahboubi, K. et al., “Desensitization of Signaling by Oncostatin M in Human Vascular Cells Involves Cytoplasmic Tyr Residue 759 in gp130 but Is Not Mediated by Either Src Homology 2 Domain-containing Tyrosine Phosphatase 2 or Suppressor of Cytokine Signaling 3,”J. Biol. Chem. (2003) 278(27): 25014-25023.
Mora, L. B. et al., “Constitutive Activation of Stat3 in Human Prostate Tumors and Cell Lines: Direct Inhibition of Stat3 Signaling Induces Apoptosis of Prostate Cancer Cells,”Cancer Res.(2002) 62(22): 6659-6666.
Niu, G. et al., “Gene Therapy with Dominant-negative Stat3 Suppresses Growth of the Murine Melanoma B16 Tumorin Vivo,” Cancer Res. (1999) 59: 5059-5063.
Niu, G. et al., “Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis,”Oncogene(2002) 21(13): 2000-2008.
Song, L. et al., “Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells,”Oncogene(2003) 22(27): 4150-4165.
Tamm, I. et al., “Antisense therapy in oncology: new hope for an old idea?”Lancet(2001) 358: 489-497.
Chin, Andrew “On the Preparation and Utilization of Isolated and Purified Oligonucleotides.” Document purportedly located on a CD-ROM and contributed to the public collection of the Katherine R. Everett Law Library of the University of North Carolina on Mar. 14, 2002.
Bowman Amy H.
Desai Manisha A.
Isis Pharmaceuticals , Inc.
Schultz J. D.
LandOfFree
Antisense oligonucleotide modulation of STAT3 expression does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antisense oligonucleotide modulation of STAT3 expression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense oligonucleotide modulation of STAT3 expression will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3621599